Is CJC-1295 Legal in Florida? How to Access It Legally

What CJC-1295 Is and Why Its Legal Status Is Complicated

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary gland and stimulates pulsatile release of endogenous growth hormone. The version most used clinically includes a drug affinity complex (DAC) modification that extends its half-life to approximately 6 to 8 days, versus roughly 30 minutes for unmodified GHRH.

No pharmaceutical company has submitted a New Drug Application (NDA) or Biologics License Application (BLA) for CJC-1295. That single fact drives every downstream legal question. Because the FDA has not approved CJC-1295 as a finished drug product, it cannot be manufactured and sold as a standard prescription medicine. The only lawful paths to human use run through the federal compounding framework or an Investigational New Drug (IND) application for research.

Why "Research Chemical" Sales Do Not Count as Legal Human Use

Online vendors frequently list CJC-1295 as a "research chemical" or "for laboratory use only." Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), selling any unapproved substance for human consumption without a valid prescription and proper compounding oversight violates federal law. The FDA has repeatedly warned that labeling a compound "not for human use" does not create a legal exemption when the intended use is clearly human. Purchasing from such vendors exposes buyers to product quality risks and potential federal legal exposure.

The Florida Layer

Florida does not have a separate state-level statute that independently legalizes or bans CJC-1295. Florida defers to the federal FD&C Act framework and overlays its own pharmacy practice rules through Chapter 465 of the Florida Statutes, enforced by the Florida Board of Pharmacy. A compounding pharmacy operating in Florida must hold a valid Florida permit and comply with both state Chapter 465 rules and federal 503A or 503B requirements simultaneously.

The Federal Compounding Framework: 503A vs. 503B

The Drug Quality and Security Act of 2013 created two distinct compounding pathways, codified at 21 U.S.C. §353a and §353b. Understanding which pathway applies to CJC-1295 determines whether a pharmacy can legally prepare it.

503A: Traditional Compounding for Individual Patients

A 503A pharmacy compounds medications for specific patients based on a valid, patient-specific prescription from a licensed practitioner. Key rules include:

• The compounded drug must not be essentially a copy of an FDA-approved commercially available product.
• It may use bulk drug substances that appear on the FDA's 503A "Category 1" list (nominated substances under review) or "Category 2" list (approved for use), or that were used in FDA-approved drugs before 1962.
• Sterile preparations require compliance with USP 797 standards.

CJC-1295 has been nominated to the 503A bulk substances list. As of mid-2025, the FDA has placed it in the review queue but has not issued a final determination approving or prohibiting its use by 503A pharmacies. The FDA publishes the current status of bulk drug substance nominations on its website. This gray-area status means some 503A pharmacies have continued compounding CJC-1295 under a policy that substances under active review may be used until a final rule is issued. Other pharmacies decline to use it pending a final decision. A prescriber ordering CJC-1295 from a 503A pharmacy should confirm the pharmacy's legal review of current FDA guidance before dispensing.

503B: Outsourcing Facilities

503B outsourcing facilities can compound without a patient-specific prescription and can sell to hospitals and clinics in larger quantities. They must register with the FDA, comply with current Good Manufacturing Practice (cGMP), and may only use bulk drug substances on the FDA's affirmative 503B list. As of the date of this article's last review, CJC-1295 does not appear on the FDA's 503B bulk drug substances list. That means 503B outsourcing facilities cannot legally compound CJC-1295 for office stock or clinic distribution under current rules.

The practical result: if you are a Florida patient seeking CJC-1295, only a 503A traditional compounding pharmacy (with a valid patient-specific prescription) represents a potentially lawful supply path as of mid-2025, and that path carries the caveat that FDA's final bulk-substance ruling could change the picture.

What a Lawful CJC-1295 Prescription Looks Like in Florida

A lawful prescription for CJC-1295 in Florida requires several elements, all of which reflect standard medical and pharmacy practice law.

Who Can Prescribe

Florida licensed physicians (MD, DO), Advanced Practice Registered Nurses (APRNs) with prescriptive authority, and Physician Assistants (PAs) with a supervising physician relationship may all prescribe CJC-1295 under their respective scopes of practice. The prescriber must hold an active, unencumbered Florida license. Telehealth prescribing is permitted under Florida Statute §456.47, provided the prescriber establishes a valid patient-provider relationship, which typically includes a medical history review, symptom assessment, and relevant lab work before the prescription is issued.

What Lab Work Is Typically Required

A clinically responsible workup before CJC-1295 prescribing generally includes:

• Fasting insulin-like growth factor 1 (IGF-1) level, the standard surrogate marker for growth hormone output
• Fasting glucose and HbA1c, because growth hormone secretagogues can transiently raise blood glucose
• A basic metabolic panel
• Thyroid-stimulating hormone (TSH), since hypothyroidism blunts GH axis response
• In some practices, a stimulation test (e.g., glucagon stimulation) if adult growth hormone deficiency is the clinical question

The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults recommends confirming GH deficiency with a stimulation test before initiating GH-axis therapy, though CJC-1295 itself is not the subject of that guideline. Prescribers applying these diagnostic standards to off-label peptide prescribing are making a defensible clinical judgment within the standard of care.

Typical Compounded Doses

CJC-1295 is most commonly compounded as a sterile lyophilized powder for subcutaneous injection. Doses seen in clinical practice range from 100 mcg to 300 mcg per injection, administered 2 to 3 times weekly for the DAC form, or nightly at similar per-dose amounts for non-DAC CJC-1295 (also called Modified GRF 1-29). Compounding pharmacies supply a bacteriostatic water diluent and syringes. The pharmacist and prescriber are responsible for ensuring the final preparation meets USP 797 sterility standards.

Clinical Evidence Supporting CJC-1295 Use

CJC-1295 has been studied in human trials, which differentiates it from many peptides that exist only in animal data.

Key Published Human Trials

A 2006 dose-escalation study by Ionescu and Frohman (N=65 healthy adults) published in the Journal of Clinical Endocrinology and Metabolism found that a single subcutaneous injection of CJC-1295 with DAC produced dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold above baseline, with effects lasting up to 6 days. IGF-1 levels increased 1.5- to 3-fold above baseline and remained elevated for 9 to 11 days after a single injection. The full data are available via PubMed (PMID 16684980).

A subsequent multiple-dose study in the same publication demonstrated that after 6 weekly or biweekly injections of CJC-1295 (1 mg/kg or 2 mg/kg), mean IGF-1 levels increased 1.7- to 2-fold above baseline and remained elevated throughout the treatment period. No serious adverse events were reported at doses up to 2 mg/kg in that cohort.

A 2010 study by Teichman and colleagues (N=16 healthy older adults, mean age 59) examined the pharmacokinetics and pharmacodynamics of CJC-1295 with DAC and found that biweekly dosing maintained IGF-1 elevations of approximately 30 to 40 percent above baseline. See PMID 16822949 via PubMed.

These trials provide proof of mechanism in humans. They do not constitute FDA approval, and they were conducted at doses (1 to 2 mg/kg) substantially higher than those typically used in compounding practice today. A prescriber citing this evidence in a patient chart is documenting an off-label use grounded in peer-reviewed human data, which is a legally and ethically different posture than prescribing based on no data.

What the Evidence Does Not Show

No large randomized controlled trial has compared CJC-1295 to placebo for body composition outcomes, bone density, or quality of life in diagnosed adult growth hormone deficiency populations. The clinical rationale for prescribing it rests on pharmacodynamic data (it raises IGF-1) combined with extrapolation from GH replacement literature. Prescribers and patients should hold that distinction clearly.

How to Access CJC-1295 Legally in Florida: Step-by-Step

The process below reflects what a compliant prescription access path looks like as of mid-2025.

Step 1. Establish Care With a Licensed Florida Prescriber

Find a physician, APRN, or PA licensed in Florida who has experience with peptide therapy or endocrinology. This can be an in-person or telehealth visit, provided the prescriber complies with Florida telehealth statute §456.47. Avoid any "clinic" that issues a prescription without a clinical consultation and lab review.

Step 2. Complete Baseline Lab Work

Order or complete the labs described above (IGF-1, fasting glucose, HbA1c, metabolic panel, TSH). Results should be reviewed before the prescription is written.

Step 3. Receive a Patient-Specific Prescription

The prescription must be issued in your name, for your specific clinical indication, with a specific dose and dosing schedule. A standing order from a clinic to a pharmacy without individual patient prescriptions does not satisfy 503A requirements.

Step 4. Verify the Compounding Pharmacy's Credentials

Confirm that the pharmacy:

• Holds a current Florida pharmacy permit (search the Florida Department of Health MQA portal)
• Is a 503A traditional compounder (not solely a 503B outsourcing facility)
• Compounds sterile preparations under USP 797 conditions
• Has reviewed the current FDA bulk substance status for CJC-1295

Step 5. Ongoing Monitoring

Plan a follow-up IGF-1 at 8 to 12 weeks after starting therapy. An IGF-1 level above the age- and sex-adjusted upper limit of normal raises concern for over-replacement, which carries theoretical risks for insulin resistance and tissue proliferation. Adjust dose or discontinue based on both lab results and symptom response.

Florida-Specific Enforcement Considerations

Florida's Board of Pharmacy can investigate and discipline pharmacies that compound drugs using bulk substances not permitted under current FDA policy. A 503A pharmacy compounding CJC-1295 during the FDA's review period takes regulatory risk that could result in a warning letter or enforcement action if the FDA ultimately places CJC-1295 on its "Category 2" negative list (substances that may not be used by 503A compounders).

The FDA issued a series of warning letters between 2020 and 2023 targeting compounders of other peptides, including BPC-157 and TB-500, after placing them on the 503A negative list. The FDA's warning letter database documents these actions. CJC-1295 has not received a warning letter as of this writing, but the regulatory trajectory for unapproved peptides has generally moved toward greater restriction, not less.

Patients bear no direct regulatory liability for receiving a compounded prescription, but they do bear the risk of supply disruption if their pharmacy faces enforcement action. Patients should ask their pharmacy directly: "Have you received any FDA correspondence regarding CJC-1295 compounding?"

The "Anti-Aging" and Sports Performance Context: Where Legal Risk Increases

Some Florida clinics market CJC-1295 explicitly for body composition, fat loss, or athletic performance enhancement. These are not recognized medical indications in any FDA-approved labeling or major endocrine society guideline. Prescribing a controlled or compounded substance for purposes of competitive athletic performance enhancement raises concerns under:

• The Florida Medical Practice Act, which requires prescriptions to serve a legitimate medical purpose
• Anti-doping rules of the World Anti-Doping Agency (WADA), which has listed CJC-1295 as a prohibited growth hormone secretagogue on its 2024 Prohibited List

A patient subject to drug testing in any sanctioned sport who uses CJC-1295 should be aware that WADA's urine and blood testing panels now include detection methods for several GHRH analogs, including CJC-1295.

Comparing CJC-1295 to FDA-Approved Growth Hormone Therapies

For context, genuine adult growth hormone deficiency is treated with FDA-approved somatropin products: somatropin (Genotropin, Humatrope, Norditropin, Nutropin AQ, Omnitrope, Saizen, Zorbtive). These are subcutaneous daily injections, typically dosed at 0.2 to 0.4 mg/day in adults, and they carry full FDA approval with extensive long-term safety data.

CJC-1295 acts upstream, stimulating endogenous GH release rather than replacing GH directly. This preserves the pulsatility of GH secretion and keeps IGF-1 elevations within a physiologic rhythm, which some clinicians consider a theoretical safety advantage. The Endocrine Society's 2019 guideline states: "We recommend against the use of GH in adults with GH deficiency-like features who do not have a biochemically confirmed diagnosis." JCEM, 2019. That recommendation applies directly to approved GH products and by reasonable extension to GH secretagogues used for the same purpose without diagnostic confirmation.

Patients with confirmed GH deficiency by stimulation testing may have a stronger clinical and legal foundation for CJC-1295 prescribing than those pursuing it for general wellness or anti-aging purposes.

Summary of Legal Access Paths in Florida

| Access Path | Legal Status in Florida (mid-2025) | |---|---| | 503A compounding pharmacy with valid Rx | Conditional. Permitted while FDA review is pending; at risk if FDA issues negative determination | | 503B outsourcing facility | Not permitted. CJC-1295 not on FDA 503B bulk substances list | | Research chemical vendor (online) | Not legal for human use regardless of labeling | | FDA-approved finished drug product | Does not exist for CJC-1295 | | IND-approved clinical trial | Legal. Currently no open trials recruiting for CJC-1295 in adults per ClinicalTrials.gov |